108 S Jackson St, Suite 300, Seattle, WA 98104
(877) 796-4362
(206) 829-4806

Authors

Jessica Oesterheld, MD

A cytochrome maven since 1992, Dr. Oesterheld is the primary content author of YouScript responsible for expansion and maintenance of the program. Her interest in cytochrome arose from clinical experiences with patients having side effects based on CYP-based drug interactions.

Dr. Oesterheld is a graduate of Mount Holyoke College and Tufts Medical School and completed residencies in General, College, and Child and Adolescent Psychiatry. She has served as Medical Director of Pharmacy Management and on the Drug Utilization Committee of MaineCare. She has authored a number of books, papers or chapters that review cytochromes and their development and interactions, including the best-selling book Concise Guide to Drug Interaction Principles for Medical Practice.

Articles and Publications

  • Wyne G, Cozza K, Oesterheld JR.,(2009). Drug Interactions: Principles for Medical Practice 3nd edition, American Psychiatry Press Inc, Washington DC.
  • Oesterheld JR, Cozza K, Sandson NB.(2008). Oral contraceptives,Psychosomatics. 2008 Mar-Apr;49:168-75.
  • Oesterheld, JR , Shader RI, Martin A. and Scahill, L, Oesterheld, JR and Martin, A.(2007). Pharmacokinetic chapter and Psychopharmacology chapter in Lewis’ Textbook of Child Psychiatry fourth edition, Williams and Wilkins, Philadelphia.
  • Cozza K, Armstrong SC, Oesterheld JR.(2006).Study Guide to Clinical Psychopharmacology: A Companion to the American Psychiatric Publishing Text of Psychopharmacology, APPI.
  • Cozza K, Armstrong S, Oesterheld JR et al.(2006). Drug interactions in Consultation-Liaison Psychiatry chapter in Blumenthal and Strain: Textbook of Consultation-Liaison Psychiatry, American Psychiatric Press Inc.
  • Wynn GH, Zapor MJ, Smith BH, Wortmann G, Oesterheld JR, Armstrong SC, Cozza KL.(2004). Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics. 2004 May-Jun;45:262-70.
  • Oesterheld JR, Armstrong SC, Cozza KL.(2004). Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics. 2004 Jan-Feb;45:84-7.
  • Oesterheld JR, Parmalee D, Shader RI.(2003). Child Psychiatry in Manual of Psychiatric Therapeutics third edition, Lippincott Williams and Wilkins Philadelphia.
  • Oesterheld JR.(2002). UGTs for Clinicians. Psychosomatics.
  • Oesterheld JR and Flockhart DA.(2002). Hepatic P450 Cytochromes-Based Drug Interactions in: Textbook of Child and Adolescent Psychiatry. Oxford University Press.
  • Martin A, Oesterheld J et al(2002). Basic Psychopharmacology in Melvin Lewis (ed) Child and Adolescent Psychiatry: A Comprehensive Textbook, third edition Lippincott Williams and Wilkins Philadelphia.
  • Oesterheld JR and Martin A.(2001). Child and Adolescent Psychopharmacology in Curriculum for Teaching Psychiatric Residents: American Society of Clinical Pharmacology.
  • Oesterheld JR.(2001). Oral contraceptives in: The Cytochromes P450 System Cozza and Armstrong (eds) American Psychiatric Association Press, Washington.
  • Shader RI and Oesterheld JR.(April 2000).(editorial):Contraceptive Effectiveness: cytochromes and induction: J Clin Psychopharmacol 20:119-121.
  • Flockhart D, Oesterheld JR.(2000). P450 cytochromes and Drug Interactions. Child and Adolesc Psychiatric Clinics of North America 9:43-76.
  • Oesterheld JR, Osser DA.(May 1999).: Obsessive Compulsive Disorder: CYP-based drug interactions. Journal of Practical Psychiatry and Behavioral Health 5:179-183.
  • Oesterheld JR.(1998). A Review of Developmental Aspects of Cytochrome P450. J Child Adolesc Psychopharmacol 8: 8:161-174.
  • Oesterheld, JR and Shader RI.(April 1998). Cytochromes: A Primer for Child Psychiatrists, J Am Acad Child Adolesc Psychiatry 37:447-450.
  • Oesterheld, JR and Kallapelli R.(February 1997). Clomipramine and grapefruit juice: changing the metabolitic ratio. (letter to editor) J Clin Psychopharmacol 17:62-63.
  • Oesterheld JR.(November 1996). Erythromycin and Clomipramine: noncompetitive inhibition of demethylation (letter to editor) J Child Adolescent Psychopharmacol 6:211-12.
  • Oesterheld JR.(June 1996). TCA cardiotoxicity: the latest (letter to the editor) J of Am Acad Child Adolesc Psychiatry 35:701-702.

Tom Polasek, PhD

Dr. Polasek, trained initially as a Pharmacist at the Flinders Medical Centre in Adelaide (Australia) before joining the Department of Clinical Pharmacology at Flinders University in 2002. After completing his PhD in drug metabolism and pharmacokinetics, Tom held lectureships in clinical pharmacology until 2012. His professional interests include all aspects of clinical pharmacology, but are particularly focused on drug interactions and inter-individual variability in pharmacokinetics. Tom is currently a medical student at Flinders University and runs a pharmacology consulting business called TP Pharmacology.

Articles and Publications

  • Polasek TM, Elliot DJ, Lewis BC, and Miners JO (2004) Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. The Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 3, pp. 996-1007.
  • Polasek TM, Elliot DJ, and Miners JO (2006) Measurement of human cytochrome P4501A2 (CYP1A2) activity in vitro. Current Protocols in Toxicology, suppl. 27, pp. 4.19.1-4.19.11.
  • Polasek TM and Miners JO (2006) Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. European Journal of Clinical Pharmacology, vol. 62, no. 3, pp. 203-208.
  • Polasek TM, Elliot DJ, Somogyi AA, Gillam EMJ, Lewis BC, and Miners JO (2006) An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. British Journal of Clinical Pharmacology, vol. 61, no. 5, pp. 570-584.
  • Polasek TM and Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opinion on Drug Metabolism and Toxicology, vol. 3, no. 3, pp. 321-329.
  • Polasek TM and Miners JO (2008) Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. British Journal of Clinical Pharmacology, vol. 65, no. 1, pp. 87-97.
  • Polasek TM, Polak S, Doogue MP, Rostami-Hodjegan A, and Miners JO (2009) Assessment of inter-individual variability in predicted phenytoin clearance. European Journal of Clinical Pharmacology, vol. 65, no. 12, pp. 1203-1210.
  • Polasek TM, Sadagopal JS, Elliot DJ, and Miners JO (2010) In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. European Journal of Clinical Pharmacology, vol. 66, no. 3, pp. 275-283.
  • Lin FPY, Anthony S, Polasek TM, Tsafnat G, Doogue MP, and Coiera E (2011) BICEPP: an example-based statistical text mining framework for predicting the binary characteristics of drugs. BMC Bioinformatics, vol. 12, no. 112.
  • Polasek TM, Lin FPY, Miners JO, and Doogue MP (2011) Perpetrators of pharmacokinetic drug-drug interactions from altered cytochrome P450 activity: a criteria-based assessment. British Journal of Clinical Pharmacology, vol. 71, no. 5, pp. 727-736.
  • Wattanachai N, Polasek TM, Health TM, Uchaipichat V, Tassaneeyakul W, Tassaneeyakul W, and Miners JO (2011) In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of inter-individual variability in predicted clearance. European Journal of Clinical Pharmacology, vol. 67, no. 8, pp. 815-824.
  • Doogue MP and Polasek TM (2011) Drug dosing in renal disease. The Clinical Biochemist Reviews, vol. 32, no. 2, pp. 69-73.
  • Polasek TM, Doogue MP and Miners (2011) Metabolic activation of clopidogrel: in vitro data provides conflicting evidence for the contributions of CYP2C19 and PON1. Therapeutic Advances in Drug Safety, vol. 2, no. 6, pp. 253-261.
  • Snyder B, Polasek TM and Doogue MP (2012) Drug interactions: principles and practice. Australian Prescriber, in press.
  • Sorich, MJ, Polasek TM and Wiese MD (2012) Systematic review of the association between cytochrome P4502C19 genotype and bleeding risk with clopidogrel. Thrombosis and Haemostasis, submitted.
  • Miners JO, Polasek TM, Mackenzie PI, and Knights KM (2010) The in vitro characterization of inhibitory drug-drug interactions involving UDP-glycuronosyltransferase. In Enzyme- and transporter-based drug-drug interactions: progress and future challengers (Eds. Pang SK, Rodrigues DA and Peter RM), pp. 217-236. Springer, New York.
  • Polasek TM (2011) Beyond CYP2C19 – a new chapter in clopidogrel pharmacogenomics. Journal of Pharmacy Practice and Research, vol. 41, no. 1, pp. 14-15.
  • Polasek TM (2011) Rapid progress on the clopidogrel PON1 story. Journal of Pharmacy Practice and Research, vol. 41, no. 4, pp. 258-259.
  • Doogue MP and Polasek TM (2012) The ABCD of clinical pharmacokinetics. British Journal of Clinical Pharmacology, submitted.
  • Polasek TM and Gebauer M (2001) Inhibition of vitamin K 2,3-epoxide (VKER) activity: a study to investigate the role of the vitamin K cycle in the interaction between paracetamol and warfarin. Proceedings: 25th Federal Conference of The Society of Hospital Pharmacists of Australia, p. 86.
  • Polasek TM, Elliot DJ, and Miners JO (2003) The effects of macrolide antibiotics on CYP3A4 and CYP1A2: in vitro studies to investigate the interaction between the macrolides and theophylline. Program Handbook: 26th Federal Conference of The Society of Hospital Pharmacists of Australia, p. 51.
  • Polasek TM, Elliot DJ, and Miners JO (2003) Inactivation of human cytochrome P4503A4 (CYP3A4) by macrolide antibiotics: prediction of in vivo interaction potential from in vitro data. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, vol. 10, Abstract 269, eds EA Davis and CG Sobey.
  • Polasek TM, Elliot DJ, and Miners JO (2004) Mechanism-based inactivation of human recombinant cytochrome P4502C8 (CYP2C8) by nortriptyline, verapamil, fluoxetine, amiodarone, isoniazid and phenelzine in vitro. Clinical and Experimental Pharmacology and Physiology, vol. 31, suppl. 1, p. A95.
  • Polasek TM, Elliot DJ, and Miners JO (2004) Mechanism-based inactivation of recombinant and human liver microsomal cytochrome P4502C8 (CYP2C8). Drug Metabolism Reviews, vol.36, suppl. 1, p. 271.
  • Polasek TM, Elliot DJ, and Miners JO (2005) Mechanism-based inactivation (MBI) of human liver microsomal cytochromes P450 by the irreversible monoamine oxidase inhibitors (MAOIs) isoniazid, phenelzine and clorgyline. Drug Metabolism Reviews, vol.37, suppl. 1, p. 25.
  • Polasek TM, Elliot DJ, and Miners JO (2005) Predicting metabolic drug-drug interactions with isoniazid: significant mechanism-based inactivation of CYP3A and CYP2C19. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Australasian Pharmaceutical Sciences Association, vol. 11, Oral 161, eds EA Davis and CG Sobey.
  • Polasek TM and Miners JO (2006) Mechanism-based inactivation (MBI) of recombinant CYP2C19 and CYP3A4 but not human liver microsomal CYP2C19 and CYP3A4 by nortriptyline. Acta Pharmacologica Sinica, vol. 27, suppl. 1, p. 100.
  • Polasek TM and Miners JO (2006) Formation of alkylamine metabolite-intermediate complexes between tricyclic antidepressants and human drug metabolising CYP: evidence for mechanism-based inactivation. Proceedings of the Australian Health and Medical Research Congress 2006, Abstract 635, p. 247.
  • Polasek TM, Elliot DJ, Lewis BC, and Miners JO (2007) Time-dependent inhibition of cytochromes P450 by monoamine oxidase inhibitors: disparity between microsomal and recombinant enzyme test systems. Proceedings: Southeast Asian Western Pacific Regional Meeting of Pharmacologists, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, vol. 12, Poster 3-60, eds CG Sobey and S Smid.
  • Polasek TM, Rowland A, Elliot DJ, Knights KM, Mackenzie PI, Polak S, Rostami-Hodjegan A, and Miners JO (2008) Incorporating inter-individual variability into the prediction of phenytoin clearance from albumin-adjusted in vitro data. Drug Metabolism Reviews, vol.40, suppl. 1, p. 51.
  • Sadagopal JS, Elliot, DJ, Lewis BC, Miners JO, and Polasek TM (2008) Mechanism-based inactivation of human cytochrome P4503A4 by zolpidem in vitro. Proceedings of the Australian Health and Medical Research Congress 2008, Abstract 805, p. 405-406.
  • Polasek TM and Doogue MP (2008) A criteria based catalogue of clinically important cytochrome P450 inhibitors and inducers. Proceedings of the Australian Health and Medical Research Congress 2008, Abstract 861, p. 426.
  • Polasek TM, Sadagopal JS, Elliot DJ, Lewis BC, and Miners JO (2009) Predicting the metabolic interaction potential of zolpidem with CYP3A drugs. Drug Metabolism Reviews, vol.41, suppl. 3, p. 72-73.
  • Polasek TM and Doogue MP (2009) Important inhibitors and inducers of cytochrome P450 enzymes: what is the clinical evidence? Conference Handbook and Book of Abstracts: 35h Society of Hospital Pharmacists of Australia National Conference, Poster 185, p. 215.
  • Deacon PM, Griffith-Jones T, Polasek TM, Mangoni AA, and Doogue MP (2009) Screening for potential drug-drug interactions by intern doctors: a survey of clinical practice. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, vol. 14, Poster 1-4, eds D Hay and S Ngo.
  • Tarafdar S, Mangoni AA, Polasek TM, and Doogue MP (2009) Laboratory reported glomerular filtration rate, a poor predictor of digoxin clearance. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, vol. 14, Oral 46, eds D Hay and S Ngo.
  • Polasek TM (2009) Mechanism-based inactivation of cytochrome P450 enzymes: a clinically important cause of metabolic drug-drug interactions. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, vol. 14, Oral 67, eds D Hay and S Ngo.
  • Doogue MP and Polasek TM (2009) Simplifying the evaluation of potential drug-drug interactions. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, vol. 14, Oral 68, eds D Hay and S Ngo.
  • Doogue MP, Polasek TM, and Lin F (2010) Prescriber evaluation of potential drug-drug interactions, room for improvement? Internal Medicine Journal, vol. 40, suppl. 1, p. 14-15.
  • Miners JO, Doogue MP, and Polasek TM (2010) Taming drug-drug interactions. National Medicines Symposium 2010, Abstract 177, p. 118.
  • Heath TM, Wattanachai N, Uchaipichat V, Tassaneeyakul W, Tassaneeyakul W, Miners JO, and Polasek TM (2010) Prediction of paclitaxel clearance from in vitro kinetic data. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, P21, http://www.ascept.org/Past-Annual-Scientific-Meetings/2010-/Proceedings.aspx
  • Barnes KJ, Doogue MP, Miners JO, and Polasek TM (2010) Assessment of cytochrome P450 inactivation efficacy as a predictor of pharmacokinetic drug-drug interactions. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, P25, http://www.ascept.org/Past-Annual-Scientific-Meetings/2010-/Proceedings.aspx
  • Lin FPY, Polasek TM, Anthony S, Tsafnat G, and Doogue MP (2010) BICEPP: a computational text mining methods for predicting the binary characteristics of drugs. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, P40, http://www.ascept.org/Past-Annual-Scientific-Meetings/2010-/Proceedings.aspx
  • Kichenadasse G, Doogue MP, Koczwara B, Karapetis C, and Polasek TM (2011) In silico assessment of erlotinib as a potential inhibitor of CYP3A-mediated drug clearance. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, New Zealand Annual Scientific Meeting, Abstract 3.4, http://www.ascept.org.nz/
  • Patel F, Jensen BP, Doogue MP and Polasek TM (2011) Effects of adults age on predicted total drug clearance. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, Poster 30, http://ascept2011.eproceedings.com.au/posters.html
  • Polasek TM, Heath TM and Doogue MP (2011) Prediction of docetaxel clearance and the ketoconazole-docetaxel interaction. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, Poster 44, http://ascept2011.eproceedings.com.au/posters.html
  • Barnes KJ, Rowland A, Polasek TM and Miners JO (2011) The inhibitory effects of uremic toxins on drug metabolising enzyme activity in vitro. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, Poster 51, http://ascept2011.eproceedings.com.au/posters.html
  • Snyder B, Rowland A, Polasek TM, Miners JO and Doogue MP (2011) An evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions in healthy volunteers using a drug cocktail approach. Proceedings: Australasian Society of Clinical and Experimental Pharmacologists, Oral 111, http://ascept2011.eproceedings.com.au/papers.html
  • Polasek TM, Heath TM, Doogue MP and Wiese MD (2011) Prediction of taxane clearance from in vitro metabolism data. Proceedings: Australian Pharmaceutical Sciences Association, PXX.

David N. Osser, MD

Dr. Osser is an international consultant in clinical psychopharmacology with over 25 years of experience in a wide variety of settings. He is best known for the development of systematic, comprehensive, algorithmic pathways for evidence-supported psychopharmacological treatment of depressive, psychotic, and anxiety disorders. In collaboration with Robert Patterson, M.D., these algorithms have been produced in an Internet-based “virtual psychopharmacology consultation” interactive computer format.

Osser is Associate Professor of Psychiatry at Harvard Medical School. He is also Attending Psychiatrist, Associate Medical Director, and Director of Academic Affairs at Taunton State Hospital. At the Brockton (MA) Veterans Affairs Hospital, he is the Psychiatrist for the Domiciliary Residential Treatment Program and Curriculum Coordinator for Psychopharmacology in the Harvard South Shore Psychiatry Residency Training Program. His main academic interest is in the development of decision-support tools that employ evidence-based reasoning, for use in the clinical practice of psychopharmacology. He is an author of over 80 academic products, including journal articles, software, monographs, book chapters, and abstracts. He has received nine awards for outstanding teaching, and two awards from the Alliance for the Mentally Ill for his dedication and service to the severely mentally ill and their families.

Dr. Osser is a member of the International Psychopharmacology Algorithm Project, directed by Kenneth Jobson, M.D. Under their auspices, he has presented his algorithms and software in Japan and China in the past several years. He has been named an “Honorary International Advisory Member of the Chinese Psychopharmacology Algorithm Project with gratitude from the Beijing University Institute of Psychiatry and the Ministry of Health of the People’s Republic of China.” He is on the editorial boards of the International Drug Therapy Newsletter, Psychiatric Times, and the Model Curriculum for Psychopharmacology of the American Society of Clinical Psychopharmacology.

David lives in Needham, Massachusetts with his wife Stephanie, two children: Rosie and Daniel, and two turtles: Hypotenuse 4.0 and Hypotenuse 5.0.


Neil B. Sandson, MD

Dr. Sandson is the Director of the Psychopharmacology Consultation Service and the Director of the Division of Education and Residency Training at Sheppard Pratt Hospital, Baltimore Maryland. He graduated from Amherst College and then the University of Maryland with an M.D. His residency was at Sheppard Pratt. Dr. Sandson is an examiner for the American Board of Psychiatry and Neurology and is a Clinical Assistant Professor of Psychiatry at the University of Maryland.

His professional interests include the cytochrome P450 system, drug-drug interactions, mechanisms of action of psychotropic agents and teaching

Articles and Publications

  • Sandson, NB: Drug Interactions Casebook: The Cytochrome P450 System and Beyond. Arlington, VA, American Psychiatric Publishing Inc., May 2003.
  • Sandson NB: Exploring Drug Interactions in Psychiatry. Psychiatric Times 21(5):44-48, 2004
  • Sandson NB: Perspectives on Psychopharmacology – Drug Interactions: A Tangled Web We Weave (Part II). The Maryland Psychiatrist, Spring 2004, 30(3):5, 14, 2004
  • Sandson NB: Drug-Drug Interactions: The Silent Epidemic. Psychiatric Services, in press.
  • Sandson NB: Perspectives on Psychopharmacology – Drug Interactions: A Tangled Web We Weave (Part I). The Maryland Psychiatrist, Winter 2003/04, 30(2):4, 9, 2004
  • Lachner C, Sandson NB: Medical Complications of Catatonia: A Case of Catatonia-Induced Deep Venous Thrombosis. Psychosomatics 44(6):512-4, 2003.
  • Lindsey RL, Kaplan D, Koliatsos V, Walters JK, Sandson, NB: Aripiprazole and extrapyramidal symptoms. J Am Acad Child Adolesc Psychiatry 42(11):1268-9, 2003.
  • Sandson NB: Perspectives on Psychopharmacology – Aripiprazole: Possibilities and Pitfalls. The Maryland Psychiatrist, Fall 2003, 30(1):8,12-13.
  • Armstrong SC, Cozza KL, Sandson NB: Med-Psych Drug-Drug Interactions Update: Six Patterns of Drug-Drug Interactions. Psychosomatics 44(3):255-258, 2003.
  • Sandson NB: Drug Interactions: A Tangled Web We Weave (Part II). M.D. Today – GBMC Health Care, May/June 2003, p. 5.

Gabriel Eckermann, MD

Dr. Eckermann graduated from the University of Munich with his M.D. and completed his General Psychiatry internship and residency at the District Clinic for Psychiatry and Neurology in Kaufbeuren (Bavaria): Germany. A psychiatrist at Bezirkskrankenhaus Kaufbeuren, District Clinic for Psychiatry and Neurology in Kaufbeuren, he is a Senior Consultant in psychiatry, and responsible for drug safety in psychiatry, at District Clinic for Psychiatry and Neurology in Kaufbeuren. He is the founder and Head of the plasma-level-testing laboratory for psychotropic drugs at the District Clinic for Psychiatry and Neurology in Kaufbeuren, and regularly conducts continuing education courses in psychopharmacology for employees of Bavarian District Hospitals and University Clinics.

Dr. Eckermann has been Senior Consultant in psychopharmacology for eight hospitals for psychiatry, neurology and psychotherapy in the southern area of Bavaria, and offers lectures on drug-drug interactions, Therapeutic Drug Monitoring (TDM), Pharmacogenetics and drug safety in Germany, Switzerland, Austria, Norway, the United Kingdom, and the United States.

Gabriel is a member of Psychiatric drug safety in Bavaria (an alliance of about 30 psychiatric hospitals in Bavaria, the Therapeutic Drug Monitoring scientific group in Germany, Switzerland, and and Austria (led by Prof. Christoph Hiemke), and the National Committee for Drugs of German Physicians, working in the group responsible for adverse drug reactions. He is also a coeditor (with Prof. C. Hiemke, Prof. E. Haen, Dr. M. Dobmeier) of a drug-drug interactions program for psychopharmacology in German: www.psiac.de.